Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback
After disappointing Phase III readouts all but decimated Roche’s expectations for etrolizumab as an ulcerative colitis treatment, the pharma giant is burying the program in its quarterly cleanup ritual.
Roche noted the change in its Q3 update, where it also disclosed scrapping two Phase I programs: RG6000, a DLK inhibitor for ALS; and RG7861, an antibody-antibiotic conjugate against S.aureus. Then there’s a discontinuation for Polivy, the Seagen-partnered ADC targeting CD79b, in follicular lymphoma for “portfolio priorities.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.